Keyword: Edmond de Rothschild Investment Partners
The series A, which was backed by Andera Partners and Canaan, will fund work to render more tumors vulnerable to checkpoint inhibitors.
The French biotech picked up the antisense oligonucleotide centronuclear myopathy prospect from its cofounder, Ionis Pharmaceuticals.
The financing equips Crescendo to show whether its vision for dialing up T-cell activity in the tumor microenvironment translates into humans.
The haul makes BioDiscovery 5 the largest fund dedicated to biotechs and medical devices in Europe and tees up De Rothschild to invest in 17 firms.
Genoa Pharmaceuticals has raised $62 million to take its lead candidate into the clinic.
MedLumics has raised $37 million to run clinical trials of its atrial fibrillation device.